BioAge Labs Inc

BioAmber, Inc. is an industrial biotechnology company, which produces sustainable chemicals. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in everyday products, including plastics, resins, paints, food additives and personal care products. The firm's products include bio-based succinic acid, butanediol and bio-based disodium succinate. The company was founded on October 15, 2008 and is headquartered in Montreal, Canada.

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

Lost Money on BioAge Labs, Inc. (BIOA)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioAge Labs, Inc. - BIOA

BioAge Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by BioAge Labs, Inc. (BIOA)

LOS ANGELES, CA / ACCESSWIRE / December 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into BioAge Labs Inc For Securities Fraud

BioAge Labs, Inc. (BIOA) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioAge Labs, Inc. (BIOA) And Encourages Shareholders to Reach Out

BIOA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your BioAge Labs, Inc. investment

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA NOTICE: BFA Law Notifies BioAge Labs Investors the Company is Under Investigation and Urges You to Contact the Firm (NASDAQ:BIOA)

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) on behalf of BioAge stockholders. Our investigation concerns whether BioAge has violated the federal securities laws and/or engaged in other unlawful business practices.

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of BioAge Stockholders and Encourages Investors to Contact the Firm

Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BIOA

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA REPORT: Suffer Losses on BioAge Labs, Inc.? You are Urged to Contact BFA Law about its Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / December 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

BioAge Labs, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholder Participation

Shareholder Rights Advocates at Levi & Korsinsky Investigate BioAge Labs, Inc. (BIOA) Regarding Possible Securities Fraud Violations

BIOA Investors with Significant Losses Encouraged to Contact the Firm BIOA Investors with Significant Losses Encouraged to Contact the Firm

BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioAge Labs, Inc. (BIOA) and Encourages Shareholders to Learn More About the Investigation

BioAge Labs, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- BIOA

Block & Leviton is investigating BioAge Labs after the company discontinued its STRIDES Phase 2 trial for azelaprag. Investors should contact the firm.

BioAge Labs Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

Did BioAge Labs, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - BIOA

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

BioAge Labs, Inc. (BIOA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA ALERT: The Investigation on behalf of BioAge Labs Shareholders is Ongoing -- Contact BFA Law if You Lost Money (NASDAQ:BIOA)

LOS ANGELES, CA / ACCESSWIRE / December 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by BioAge Labs, Inc. (BIOA)

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

News for BioAge Labs Inc Stock (BIOA)